Compare Nutrien Ltd (NTR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Zimmer Biomet Holdings Inc — how do they compare? Nutrien Ltd trades at $67.48 (market cap $33.31B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Nutrien Ltd is the larger of the two by market cap, and Nutrien Ltd pays the higher dividend (3.15%). Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 59 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| NTR | ZBH | |
|---|---|---|
Market Cap | $33.31B | $16.95B |
Volume | 1,330,729 | 2,505,240 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $103.98 |
52-Week Low | $53.64 | $79.58 |
Typical Hold Time | 59 Days | 89 Days |
Enterprise Value | $45.11B | $24.02B |
Dividend Yield | 3.15% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.87, down 0.14% with a bearish technical signal despite positive analyst sentiment. The company shows improving fundamentals with 2025 revenue of $26.89B and net income of $2.27B, representing an 8.44% margin. Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing estimates. Cash flow trends indicate operational strength with $4.01B from operations in 2025, though net cash flow remains negative. The stock faces headwinds from fertilizer industry challenges but benefits from strong potash demand and cost discipline.
NTR presents a moderate buy opportunity with 60.61% analyst buy ratings and $76.14 consensus price target offering 9% upside. Key catalysts include November 2026 Investor Day and structural gas arbitrage benefits, while risks involve fertilizer price volatility, geopolitical supply disruptions, and sulfur cost pressures. The company's North American nitrogen assets provide competitive advantage, but investors should monitor agricultural cycle trends and input cost management.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
